Search

Displaying results 5741 - 5750 of 10000 in total
  1. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent … T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis.

    Categories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors, HER2 Receptor AntagonistsSynonyms: T-DM1
  2. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C. … The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine.

  3. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    Col-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist. … It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.

  4. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

  5. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  6. Drug

    NBI-6024

    go.drugbank.com/drugs/DB05819
    Investigational

    NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.

  7. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  8. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology. … It provides patients with long term therapeutic benefit from a single administration rather than multiple injections.

    Synonyms: Prolease-r-hFSH
  9. Drug

    G207

    go.drugbank.com/drugs/DB05827
    Investigational

    MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.

    Synonyms: G 207, G-207
  10. Drug

    Parathyroid hormone

    go.drugbank.com/drugs/DB05829
    ApprovedInvestigational

    Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. … , leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa).

    Synonyms: PTH(1-84), rPTH(1-84)